High Court Gives Hope to Devotees with Autoimmune and Rare Diseases in Tirumala Temple
court gives devotees:
Hindu Pilgrims with Autoimmune and Rare Diseases Get Hope in Indian Temple
In a significant development for devotees with severe health conditions, the High Court of Hyderabad has directed the Tirumala Tirupati Devasthanams (TTD) to make a decision on allocating darshan (a special moment of spiritual union) quotas for individuals suffering from autoimmune disorders, rare diseases, and serious haematological conditions within the next four months.
This order is a testament to the growing recognition of the intersection of spirituality and healthcare in India.
Updated: May 7, 2026
Hindu Pilgrims with Autoimmune and Rare Diseases Get Hope in Indian Temple
In a significant development for devotees with severe health conditions, the High Court of Hyderabad has directed the Tirumala Tirupati Devasthanams (TTD) to make a decision on allocating darshan (a special moment of spiritual union) quotas for individuals suffering from autoimmune disorders, rare diseases, and serious haematological conditions within the next four months. This order is a testament to the growing recognition of the intersection of spirituality and healthcare in India.
What Happened
On April 28, a petitioner approached the High Court, seeking an amendment to the TTD’s current darshan quota for medical cases. The petitioner’s primary demand was for the inclusion of individuals suffering from severe autoimmune disorders, rare diseases, and serious haematological conditions. The High Court, in its order, directed the TTD to make a decision within a specified timeframe.
Background Timeline
The TTD, the governing body of the Tirumala Venkateswara Temple in Andhra Pradesh, has been offering special darshan quotas for individuals with medical conditions since 2005. This initiative was aimed at providing devotees with an opportunity to visit the temple without causing undue burden on their health. Over the years, the TTD has periodically reviewed and revised its darshan quota policy to cater to the growing needs of devotees.
Key Concerns
Several key concerns are central to this controversy. Firstly, there is an increasing number of devotees with severe autoimmune and rare diseases, who, despite their physical limitations, wish to visit the temple for spiritual solace. Secondly, the existing TTD policy has been criticized for its arbitrary exclusion of conditions that pose significant health risks. Lastly, the TTD’s decision-making process has been criticized for being opaque and inconsistent.
What’s Next
The High Court’s order is a significant step towards resolving this long-standing controversy. In the next four months, the TTD is expected to deliberate on the petitioner’s demand and make a decision on the allocation of darshan quotas for individuals suffering from autoimmune disorders, rare diseases, and serious haematological conditions. This decision will have significant implications for devotees with severe health conditions and their families. If the TTD includes these conditions in its special darshan quota, it will demonstrate a commitment to accessibility and inclusion, setting a new precedent for other temples and institutions in India.
The High Court’s directive to the Tirumala Tirupati Devasthanams highlights India’s evolving understanding of the intersection of spirituality and healthcare, where compassion meets devotion. This decision may pave the way for a more inclusive approach to temple visits, where devotees with severe health conditions can experience a deeper connection with their faith without sacrificing their well-being.
This is a developing story. More updates will follow as new information becomes available.
This article may be prepared with the assistance of artificial intelligence (AI) and is reviewed before publication. While we aim for accuracy and timeliness, readers should verify important facts from official or primary sources. If you believe any information is inaccurate or that any content infringes your rights, please contact ainewsbreaking.com for review and appropriate action.
